Compare Repligen Corporation Common Stock (RGEN) vs Vishay Intertechnology Inc. Common Stock (VSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vishay Intertechnology Inc. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Vishay Intertechnology Inc. Common Stock trades at $27.88 (market cap $4.87B). The key difference: Repligen Corporation Common Stock is far larger — about 2.3× Vishay Intertechnology Inc. Common Stock's market cap, and Vishay Intertechnology Inc. Common Stock pays a 1.26% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vishay Intertechnology Inc. Common Stock for 6 Days on average.
| RGEN | VSH | |
|---|---|---|
Market Cap | $11.14B | $4.87B |
Volume | 1,259,263 | 2,805,188 |
Sector | Health | Technology |
52-Week High | $194.57 | $64.90 |
52-Week Low | $102.87 | $11.82 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $4.67B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Vishay Intertechnology (VSH) trades at $31.76, down 0.84% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a high P/E ratio of 158.8 but improving profitability trends, with net income projected to turn positive in 2026. Recent news highlights the company's focus on EV and AI infrastructure solutions, positioning it for growth in key technology markets.
While analyst consensus remains positive with a $43 price target, investors face valuation concerns and execution risks. The technical outlook suggests near-term pressure, but long-term growth potential exists if the company can capitalize on automotive and AI semiconductor demand while improving profit margins from current low levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vishay Intertechnology Inc. Common Stock
Vishay Intertechnology manufactures discrete semiconductors and passive electronic components. Its products include diodes, MOSFETs, resistors, capacitors, and sensors.
Read more on VSH →
